Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cann American Corp. (CNNA)
Cloverdale, CA, US
Cann American Corp. is an early-stage enterprise dedicated to developing specialized Cannabis sativa varieties designed for animal consumption. The company's strategic focus is on markets within various European Union countries. Established in 2004 and headquartered in Cloverdale, California, Cann American Corp. previously operated as Canamed4Pets, Inc. before officially rebranding in December 2019.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00% | +35.71% | +35.71% | +26.67% | -9.52% | -5.00% | -50.00% | -82.73% | -89.39% | -36.67% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%— Q3'20: -62.9% (vs Q3'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-72.6% Q3'20: -16,211.3% (vs Q3'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%— Q3'20: -6,982.2% (vs Q3'19)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%— Q3'20: -7,986.6% (vs Q3'19)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'20: -904.4% (vs Q3'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+31.9% Q3'20: -53.3% (vs Q3'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×— Q3'20: 0.00× (vs Q3'19)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Henrik Dahlerup | 25.43M | 27.50% | 25.43M | — | 25.43M | 10.00 | IN | Denmark | 2011-03-15 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-01-25 | WONG GARRY E | Director | — | D | Common | 0 | 0.00 | — | 88,500,000 | — | ↗ |
| 2011-01-25 | SCHIORRING KRISTIAN | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 25,428,334 | — | ↗ |
| 2011-01-25 | DAHLERUP HENRIK | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 25,428,333 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jason R. Tucker | Chief Financial Officer, Chief Executive Officer, Secretary, Treasurer & Director | — | male |
| Michael G. Kramer | President, Chief Operating Officer and Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CNNA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
